Kidder Stephen W Acquires 164 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Kidder Stephen W boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,130 shares of the pharmaceutical company’s stock after purchasing an additional 164 shares during the period. Vertex Pharmaceuticals makes up 1.6% of Kidder Stephen W’s portfolio, making the stock its 24th largest position. Kidder Stephen W’s holdings in Vertex Pharmaceuticals were worth $5,400,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Brighton Jones LLC raised its stake in shares of Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after acquiring an additional 579 shares during the last quarter. NBC Securities Inc. bought a new position in shares of Vertex Pharmaceuticals during the first quarter valued at about $167,000. OLD National Bancorp IN bought a new position in shares of Vertex Pharmaceuticals during the first quarter valued at about $249,000. Capital Investment Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 22.6% during the first quarter. Capital Investment Advisors LLC now owns 1,032 shares of the pharmaceutical company’s stock valued at $500,000 after acquiring an additional 190 shares during the last quarter. Finally, Daymark Wealth Partners LLC bought a new position in shares of Vertex Pharmaceuticals during the first quarter valued at about $226,000. 90.96% of the stock is owned by institutional investors.

Insider Transactions at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs bought 5,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The shares were acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company’s stock, valued at $17,535,600. The trade was a 12.50% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Citigroup upped their price objective on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a “buy” rating in a research note on Thursday, October 2nd. Raymond James Financial assumed coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, September 2nd. They set a “market perform” rating for the company. Wells Fargo & Company raised shares of Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 price objective for the company in a research note on Wednesday, August 6th. Guggenheim lowered their price objective on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Finally, Wall Street Zen cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $493.81.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $410.28 on Wednesday. The stock has a market capitalization of $105.19 billion, a P/E ratio of 29.33 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88. The company’s 50-day moving average is $396.79 and its 200 day moving average is $441.11.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.90 billion. During the same quarter in the prior year, the company earned ($12.83) earnings per share. The business’s revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.